New financing follows on from $9.8M investment made by firm last year. Warburg Pincus made a C$8.3 million (about $8.1 million) investment in Protox Therapeutics as part of a previously agreed ...
PRX302 is currently in North American Phase II evaluation as PSA-activated pore-punching prodrug. Kissei Pharamaceutical is paying Protox Therapeutics $3 million up front for exclusive Japanese rights ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback